Arca
Skip to content
Tools
Tools

Sodium/potassium-transporting ATPase

Complex group in Homo sapiens that 6 drugs act on.

  • Drugs that act on it: 6
  • Approved: 4
  • In phases 1 to 3: 2
  • Sponsors: 3
  • Genes: 8

Who is on it, and how far along

Every drug ChEMBL records acting on ATP1A1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 6

Approved4

  • Digoxin
  • Acetyldigitoxin
  • Deslanoside
  • Digitoxin

Phase 30

    Phase 22

    • Istaroxime
    • Lanatoside c

    Phase 10

      Sponsors

      Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Sodium/potassium-transporting ATPase inhibitor.
      DigoxinApprovedAzurity PharmaceuticalsSmall moleculeInhibitor29
      AcetyldigitoxinApprovedNovartis PharmaceuticalsSmall moleculeInhibitor0
      DeslanosideApprovedNovartis PharmaceuticalsSmall moleculeInhibitor0
      DigitoxinApproved—Small moleculeInhibitor0
      IstaroximePhase 2Seismic Pharmaceuticals Operations LLCSmall moleculeInhibitor2
      Lanatoside cPhase 2—Small moleculeInhibitor0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 10 in all, from ClinicalTrials.gov.
      An Evaluation of the Potential for VH4011499 Drug-drug-interactionsDigoxinPhase 1Not yet recruitingViiV HealthcareNov 16, 2026
      Artificial Intelligence-enabled Management of Atrial Fibrillation(ABLE-AF Trial)DigoxinNot applicableNot yet recruitingKorea University Anam HospitalNov 16, 2026
      A Multiple-dose Study Investigating the Drug-drug Interaction Potential and QTc Effects of Fosmanogepix in Healthy Adult SubjectsDigoxinPhase 1RecruitingBasilea PharmaceuticaOct 19, 2026
      A Phase I Study of the Interaction of D-2570 With Other Drugs in Healthy AdultsDigoxinPhase 1Not yet recruitingInventisBio Co., LtdOct 15, 2026
      An Open-label DDI Study to Investigate the Effect of Rilzabrutinib on P-gp, BCRP, OATP1B1 and OATP1B3 InhibitionDigoxinPhase 1Active, not recruitingSanofiOct 2, 2026
      Phase I Drug-Drug Interaction Study of UBT251 Injection in Participants With Overweight or ObesityDigoxinPhase 1RecruitingThe United Bio-Technology (Hengqin) Co., Ltd.Aug 25, 2026
      Randomized Evaluation of Istaroxime for Stabilization in Acute Heart Failure-Cardiogenic ShockIstaroximePhase 2 / Phase 3RecruitingSeismic Pharmaceuticals Operations LLCMay 13, 2026
      Drug-Drug Interactions of JMKX003142 in Healthy ParticipantsDigoxinPhase 1Not yet recruitingJemincareMay 4, 2026
      Drug-drug Interaction Study of ZT002 Injection in Overweight and Obese ParticipantsDigoxinPhase 1Active, not recruitingBeijing QL Biopharmaceutical Co.,LtdApr 24, 2026
      A Safety and Efficacy Trial of Istaroxime for Cardiogenic Shock Stage CIstaroximePhase 1 / Phase 2Active, not recruitingWindtree TherapeuticsAug 3, 2023

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2095186, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.